Practical photodynamic therapy for the Canadian dermatologist

Authors

  • Toni Burbidge, MD, FRCPC

Abstract

Photodynamic therapy (PDT) is used in dermatology for the treatment of malignant and non-malignant cutaneous diseases. PDT utilizes a photosensitizing agent and visible light in the presence of oxygen to produce reactive oxygen species (ROS). ROS then induce apoptosis of cellular components leading to cell death. PDT is approved in Canada for the treatment of non-hyperkeratotic actinic keratoses (AK) and superficial basal cell carcinoma (BCC) outside the H-zone of the face. In addition, some European countries have approved its use in the treatment of squamous cell carcinoma in-situ (SCCis) and thin nodular BCC.

Off-label uses of PDT include acne, photoaging, infectious dermatoses, and malignancies such as cutaneous T cell lymphoma (CTCL), and extra-mammary Paget’s disease. This review will focus on the practical use of PDT for the treatment of premalignant and malignant lesions.

Author Biography

Toni Burbidge, MD, FRCPC

Dr. Toni Burbidge is a dermatologist based in Calgary, Alberta where she practices medical and surgical dermatology. She is dual board-certified in both Canada and the United States. She completed her medical degree at the University of Toronto, and dermatology residency at the University of Calgary. She has a special interest in cutaneous oncology and is involved in melanoma research with the multi-disciplinary cutaneous oncology team at the Tom Baker Cancer Centre in Calgary. She also teaches medical residents and other learners in her affiliation with the University of Calgary as a clinical lecturer.

References

Henderson BW, Dougherty TJ. How does photodynamic therapy work?. Photochem Photobiol. 1992;55(1):145-157. doi:10.1111/j.1751-1097.1992.tb04222.x.

Galderma Canada Inc. Metvix (methyl aminolevulinate topical cream) [product monograph]. Health Canada website. Revised March 30, 2017. Accessed September 9, 2020.

Clarion Medical Technologies Inc. Levulan Kerastick [product monograph]. Health Canada website. Revised September 30, 2014. Accessed September 9, 2020.

Morton CA, Szeimies RM, Basset-Seguin N, et al. European Dermatology Forum guidelines on topical photodynamic therapy 2019 Part 1: treatment delivery and established indications – actinic keratoses, Bowen’s disease and basal cell carcinomas. J Eur Acad Dermatol Venereol. 2019;33(12):2225-2238. doi:10.1111/jdv.16017.

Morton CA, Szeimies RM, Basset-Séguin N, et al. European Dermatology Forum guidelines on topical photodynamic therapy 2019 Part 2: emerging indications – field cancerization, photorejuvenation and inflammatory/infective dermatoses. J Eur Acad Dermatol Venereol. 2020;34(1):17-29. doi:10.1111/jdv.16044.

Lui H, Richer V. Photodynamic therapy. In: Bolognia J, ed. Dermatology. 4th ed. Philadelphia, PA: Elsevier; 2018:2341-2353.

Jetter N, Chandan N, Wang S, Tsoukas M. Field Cancerization Therapies for Management of Actinic Keratosis: A Narrative Review. Am J Clin Dermatol. 2018;19(4):543-557. doi:10.1007/s40257-018-0348-7.

Ozog DM, Rkein AM, Fabi SG, et al. Photodynamic Therapy: A Clinical Consensus Guide [published correction appears in Dermatol Surg. 2017 Feb;43(2):319]. Dermatol Surg. 2016;42(7):804-827. doi:10.1097/DSS.0000000000000800.

BC Cancer. BC Cancer Protocol Summary for Topical Therapy for Skin Cancer with PDT (Photodynamic Therapy). BC Cancer Website. Accessed September 10, 2020.

Philipp-Dormston WG, Karrer S, Petering H, et al. Daylight PDT with MAL–current data and practical recommendations of an expert panel. J Dtsch Dermatol Ges. 2015;13(12):1240-1249. doi:10.1111/ddg.12807.

Dirschka T, Radny P, Dominicus R, et al. Long-term (6 and 12 months) follow-up of two prospective, randomized, controlled phase III trials of photodynamic therapy with BF-200 ALA and methyl aminolaevulinate for the treatment of actinic keratosis. Br J Dermatol. 2013;168(4):825-836. doi:10.1111/bjd.12158.

Tschen EH, Wong DS, Pariser DM, et al. Photodynamic therapy using aminolaevulinic acid for patients with nonhyperkeratotic actinic keratoses of the face and scalp: phase IV multicentre clinical trial with 12-month follow up. Br J Dermatol. 2006;155(6):1262-1269. doi:10.1111/j.1365-2133.2006.07520.x.

Morton C, Campbell S, Gupta G, et al. Intraindividual, right-left comparison of topical methyl aminolaevulinate-photodynamic therapy and cryotherapy in subjects with actinic keratoses: a multicentre, randomized controlled study. Br J Dermatol. 2006;155(5):1029-1036. doi:10.1111/j.1365-2133.2006.07470.x.

Zane C, Facchinetti E, Rossi MT, Specchia C, Calzavara-Pinton PG. A randomized clinical trial of photodynamic therapy with methyl aminolaevulinate vs. diclofenac 3% plus hyaluronic acid gel for the treatment of multiple actinic keratoses of the face and scalp. Br J Dermatol. 2014;170(5):1143-1150. doi:10.1111/bjd.12844.

Holzer G, Pinkowicz A, Radakovic S, Schmidt JB, Tanew A. Randomized controlled trial comparing 35% trichloroacetic acid peel and 5-aminolaevulinic acid photodynamic therapy for treating multiple actinic keratosis. Br J Dermatol. 2017;176(5):1155-1161. doi:10.1111/bjd.15272.

Kurwa HA, Yong-Gee SA, Seed PT, Markey AC, Barlow RJ. A randomized paired comparison of photodynamic therapy and topical 5-fluorouracil in the treatment of actinic keratoses. J Am Acad Dermatol. 1999;41(3 Pt 1):414-418. doi:10.1016/s0190-9622(99)70114-3.

Jansen MHE, Kessels JPHM, Nelemans PJ, et al. Randomized Trial of Four Treatment Approaches for Actinic Keratosis. N Engl J Med. 2019;380(10):935-946. doi:10.1056/NEJMoa1811850.

Berman B, Nestor MS, Newburger J, Park H, Swenson N. Treatment of facial actinic keratoses with aminolevulinic acid photodynamic therapy (ALA-PDT) or ingenol mebutate 0.015% gel with and without prior treatment with ALA-PDT. J Drugs Dermatol. 2014;13(11):1353-1356.

Patel G, Armstrong AW, Eisen DB. Efficacy of photodynamic therapy vs other interventions in randomized clinical trials for the treatment of actinic keratoses: a systematic review and meta-analysis. JAMA Dermatol. 2014;150(12):1281-1288. doi:10.1001/jamadermatol.2014.1253.

Basset-Seguin N, Ibbotson SH, Emtestam L, et al. Topical methyl aminolaevulinate photodynamic therapy versus cryotherapy for superficial basal cell carcinoma: a 5 year randomized trial. Eur J Dermatol. 2008;18(5):547-553. doi:10.1684/ejd.2008.0472.

Calzavara-Pinton PG, Venturini M, Sala R, et al. Methylaminolaevulinate-based photodynamic therapy of Bowen’s disease and squamous cell carcinoma. Br J Dermatol. 2008;159(1):137-144. doi:10.1111/j.1365-2133.2008.08593.x.

Wiegell SR, Fabricius S, Stender IM, et al. A randomized, multicentre study of directed daylight exposure times of 1½ vs. 2½ h in daylight-mediated photodynamic therapy with methyl aminolaevulinate in patients with multiple thin actinic keratoses of the face and scalp. Br J Dermatol. 2011;164(5):1083-1090. doi:10.1111/j.1365-2133.2011.10209.x.

Demay SDJ, Sharma K, Sapra S, Sapra R, Sapra P. Daylight-Mediated Photodynamic Therapy With Methyl Aminolevulinate in Actinic Keratosis Treatment. J Cutan Med Surg. 2018;22(3):267-272. doi:10.1177/1203475417752367.

Rubel DM, Spelman L, Murrell DF, et al. Daylight photodynamic therapy with methyl aminolevulinate cream as a convenient, similarly effective, nearly painless alternative to conventional photodynamic therapy in actinic keratosis treatment: a randomized controlled trial. Br J Dermatol. 2014;171(5):1164-1171. doi:10.1111/bjd.13138.

Lacour JP, Ulrich C, Gilaberte Y, et al. Daylight photodynamic therapy with methyl aminolevulinate cream is effective and nearly painless in treating actinic keratoses: a randomised, investigator-blinded, controlled, phase III study throughout Europe. J Eur Acad Dermatol Venereol. 2015;29(12):2342-2348. doi:10.1111/jdv.13228.

Alexiades M. Randomized, Controlled Trial of Fractional Carbon Dioxide Laser Resurfacing Followed by Ultrashort Incubation Aminolevulinic Acid Blue Light Photodynamic Therapy for Actinic Keratosis. Dermatologic surgery:official publication for American Society for Dermatologic Surgery [et al]. 2017;43(8):1053–64. doi:10.1097/dss.0000000000001117.

Petukhova TA, Hassoun LA, Foolad N, Barath M, Sivamani RK. Effect of Expedited Microneedle-Assisted Photodynamic Therapy for Field Treatment of Actinic Keratoses: A Randomized Clinical Trial. JAMA dermatol. 2017;153(7):637–43. doi:10.1001/jamadermatol.2017.0849.

Heppt MV, Steeb T, Leiter U, Berking C. Efficacy of photodynamic therapy combined with topical interventions for the treatment of actinic keratosis: a meta-analysis. J Eur Acad Dermatol Venereol. 2019;33(5):863-873. doi:10.1111/jdv.15459.

Torezan L, Grinblat B, Haedersdal M, Valente N, Festa-Neto C, Szeimies RM. A randomized split-scalp study comparing calcipotriol-assisted methyl aminolaevulinate photodynamic therapy (MAL-PDT) with conventional MAL-PDT for the treatment of actinic keratosis. Br J Dermatol. 2018;179(4):829–35. doi:10.1111/bjd.16473.

Willey A, Anderson RR, Sakamoto FH. Temperature-Modulated Photodynamic Therapy for the Treatment of Actinic Keratosis on the Extremities: A One-Year Follow-up Study. Dermatol Surg. 2015;41(11):1290-1295. doi:10.1097/DSS.0000000000000512.

Ibbotson SH, Wong TH, Morton CA, et al. Adverse effects of topical photodynamic therapy: a consensus review and approach to management. Br J Dermatol. 2019;180(4):715-729. doi:10.1111/bjd.17131.

Waters AJ, Ibbotson SH. Parameters associated with severe pain during photodynamic therapy: results of a large Scottish series. Br J Dermatol. 2011;165(3):696-698. doi:10.1111/j.1365-2133.2011.10429.x.

Babilas P, Schreml S, Landthaler M, Szeimies RM. Photodynamic therapy in dermatology: state-of-the-art. Photodermatol Photoimmunol Photomed. 2010;26(3):118-132. doi:10.1111/j.1600-0781.2010.00507.x.

Pastor-Nieto MA, Olivares M, Sánchez-Herreros C, Belmar P, De Eusebio E. Occupational allergic contact dermatitis from methyl aminolevulinate. Dermatitis. 2011;22(4):216-219.

Downloads

Published

2020-11-01

How to Cite

1.
Burbidge T. Practical photodynamic therapy for the Canadian dermatologist. Can Dermatol Today [Internet]. 2020 Nov. 1 [cited 2024 Dec. 25];1(4):24-8. Available from: https://canadiandermatologytoday.com/article/view/1-4-burbidge

Issue

Volume 1, Issue 4, November 2020

Section

Articles